Ghosh et al., 2017 - Google Patents
Synthesis of a fluorescently labeled 68Ga-DOTA-TOC analog for somatostatin receptor targetingGhosh et al., 2017
View HTML- Document ID
- 12021727906621671542
- Author
- Ghosh S
- Hernandez Vargas S
- Rodriguez M
- Kossatz S
- Voss J
- Carmon K
- Reiner T
- Schonbrunn A
- Azhdarinia A
- Publication year
- Publication venue
- ACS medicinal chemistry letters
External Links
Snippet
Fluorescently labeled imaging agents can identify surgical margins in real-time to help achieve complete resections and minimize the likelihood of local recurrence. However, photon attenuation limits fluorescence-based imaging to superficial lesions or lesions that …
- 102000011096 Somatostatin receptor family 0 title abstract description 39
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghosh et al. | Synthesis of a fluorescently labeled 68Ga-DOTA-TOC analog for somatostatin receptor targeting | |
| Kiess et al. | Prostate-specific membrane antigen as a target for cancer imaging and therapy | |
| Edwards et al. | Agonist− Antagonist Dilemma in Molecular Imaging: Evaluation of a Monomolecular Multimodal Imaging Agent for the Somatostatin Receptor | |
| Kobayashi et al. | Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging | |
| Chen et al. | Target-or-clear zirconium-89 labeled silica nanoparticles for enhanced cancer-directed uptake in melanoma: a comparison of radiolabeling strategies | |
| Farkas et al. | 64cu-and 68ga-based pet imaging of folate receptor-positive tumors: Development and evaluation of an albumin-binding NODAGA–Folate | |
| A Foss et al. | GCPII imaging and cancer | |
| Ghosh et al. | Multimodal chelation platform for near-infrared fluorescence/nuclear imaging | |
| Wängler et al. | Antibody− dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity | |
| Ogawa et al. | Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection | |
| Miao et al. | Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein | |
| Bunschoten et al. | Tailoring fluorescent dyes to optimize a hybrid RGD-tracer | |
| Chen et al. | Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging | |
| Keinänen et al. | Dual radionuclide theranostic pretargeting | |
| Lesniak et al. | Evaluation of PSMA-targeted PAMAM dendrimer nanoparticles in a murine model of prostate cancer | |
| Rainone et al. | Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer | |
| Ariztia et al. | PET/fluorescence imaging: An overview of the chemical strategies to build dual imaging tools | |
| Chen et al. | Ultrasmall renally clearable silica nanoparticles target prostate cancer | |
| Levi et al. | A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer | |
| Summer et al. | Cyclic versus noncyclic chelating scaffold for 89Zr-labeled ZEGFR: 2377 affibody bioconjugates targeting epidermal growth factor receptor overexpression | |
| Chen et al. | Synthesis and preclinical evaluation of folate-NOTA-Al18F for PET imaging of folate-receptor-positive tumors | |
| Lu et al. | A dual reporter iodinated labeling reagent for cancer positron emission tomography imaging and fluorescence-guided surgery | |
| Harmatys et al. | Tuning pharmacokinetics to improve tumor accumulation of a prostate-specific membrane antigen-targeted phototheranostic agent | |
| Deng et al. | Synthesis and evaluation of 64Cu-DOTA-NT-Cy5. 5 as a dual-modality PET/fluorescence probe to image neurotensin receptor-positive tumor | |
| Sengupta et al. | Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer |